Abpro Holdings, Inc. reported a net loss of $1.0 million for the first quarter of 2026, a significant improvement compared to a net loss of $3.9 million during the same period in 2025. The company's total operating expenses decreased to $933,000, down from $2.96 million in the prior year, primarily due to reduced research and development costs as personnel were furloughed and subsequently terminated. Research and development expenses fell to $13,000 from $325,000, while general and administrative expenses decreased to $920,000 from $2.63 million, reflecting cost-cutting measures implemented in late 2025.
Abpro's financial position showed a substantial increase in total assets, which rose to $6.87 million as of March 31, 2026, compared to $1.06 million at the end of 2025. This increase was largely attributed to the issuance of 3,162,785 shares of common stock, generating approximately $7.26 million in gross proceeds under the Standby Equity Purchase Agreement (SEPA). The company’s cash position improved significantly, with cash and restricted cash totaling $5.41 million at the end of the quarter, compared to $1.41 million a year earlier.
The company has faced challenges, including a delisting from the Nasdaq stock exchange, effective February 23, 2026, due to non-compliance with minimum bid price requirements. Following this, Abpro's shares began trading on the OTCQB market under the ticker symbol "ABPO." The company is currently appealing the delisting decision and is actively seeking additional funding through equity and debt financing, collaboration agreements, and research grants to support its operations and product development.
As of March 31, 2026, Abpro had an accumulated deficit of $120 million and reported that its cash reserves would not be sufficient to sustain operations for the next 12 months without additional capital. The company is focused on advancing its product candidates, particularly ABP-102 and ABP-201, which are in various stages of development for treating severe diseases. Management has expressed substantial doubt regarding the company's ability to continue as a going concern if it cannot secure the necessary funding.
About Abpro Holdings, Inc.
Abpro Holdings, Inc. is a biotechnology company developing next-generation antibody therapeutics for immuno-oncology and ophthalmology. Utilizing proprietary DiversImmune® and MultiMab™ platforms, it engineers multi-specific antibodies, including its TetraBi format, to target diseases like HER2+ solid tumors and vascular eye disorders. The company advances a pipeline of antibody candidates through strategic global partnerships, focusing on improved efficacy, safety, and dosing convenience in large, unmet medical markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov